抑癌基因p16抗体

抑癌基因p16抗体

收藏
  • ¥1900
  • Biorigin
  • 2025年07月31日
  • IHC-P,
  • Human,
avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 技术资料
    • 适应物种

      Human,

    • 应用范围

      IHC-P,

    • 抗体英文名

      CDKN2A/p16-INK4a

    • 规格

      100ul

    英文名称 CDKN2A/p16-INK4a
    中文名称 抑癌基因p16抗体
    别    名 cyclin-dependent kinase inhibitor 2A; CDK4I; p16-INK4; p16-INK4a; cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2A, isoform 1; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cell cycle inhibitor; cyclin-dependent kinase inhibitor 2a p16Ink4a; cell cycle regulator; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 2; Cdkn2a; Arf; INK4A; MTS1; p16; p16Cdkn2a; p19ARF; CD2A2_HUMAN.  

     

     

    研究领域 肿瘤  细胞生物  免疫学  信号转导  细胞凋亡  细胞周期蛋白  
    抗体来源 Rabbit
    克隆类型 Polyclonal
    交叉反应 Human, 
    产品应用 ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 (石蜡切片需做抗原修复)
    not yet tested in other applications.
    optimal dilutions/concentrations should be determined by the end user.
    分 子 量 17kDa
    细胞定位 细胞核 细胞浆 
    性    状 Liquid
    浓    度 1mg/ml
    免 疫 原 KLH conjugated synthetic peptide derived from human CDKN2A/p16-INK4a:81-156/156 
    亚    型 IgG
    纯化方法 affinity purified by Protein A
    储 存 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
    保存条件 Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
    PubMed PubMed
    产品介绍 This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012].

    Function:
    Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.

    Subunit:
    Heterodimer with CDK4 or CDK6. Predominant p16 complexes contained CDK6. Interacts (isoforms 1,2 and 4) with CDK4 (both 'T-172'-phosphorylated and non-phosphorylated forms); the interaction inhibits cyclin D-CDK4 kinase activity. Interacts with ISCO2.

    Subcellular Location:
    Cytoplasm. Nucleus.

    Tissue Specificity:
    Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific.

    DISEASE:
    ote=The association between cutaneous and uveal melanomas in some families suggests that mutations in CDKN2A may account for a proportion of uveal melanomas. However, CDKN2A mutations are rarely found in uveal melanoma patients.
    Defects in CDKN2A are the cause of cutaneous malignant melanoma type 2 (CMM2) [MIM:155601]. Malignant melanoma is a malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites.
    Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC) [MIM:606719].
    Defects in CDKN2A are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. [DISEASE] Defects in CDKN2A are the cause of melanoma-astrocytoma syndrome (MASTS) [MIM:155755]. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma.

    Similarity:
    Belongs to the CDKN2 cyclin-dependent kinase inhibitor family.
    Contains 4 ANK repeats.

    SWISS:
    P42771

    Gene ID:
    1029

    Database links:

    Entrez Gene: 1029 Human

    Omim: 600160 Human

    SwissProt: P42771 Human

    Unigene: 512599 Human

     



    Important Note:
    This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

     

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    询价
    上海信裕生物科技有限公司
    2025年07月16日询价
    ¥1000
    上海烜雅生物科技有限公司
    2025年07月16日询价
    ¥600
    上海晅科生物科技有限公司
    2025年12月09日询价
    询价
    上海莼试生物技术有限公司
    2025年07月12日询价
    询价
    上海研谨生物科技有限公司
    2025年10月29日询价
    抑癌基因p16抗体
    ¥1900